Pill Pals Customer Service - Pill Pals® - The Express Pharmacy

Generic Drugs Program 2024 Fiscal Year Web Posting

by Pill Pals Customer Service | Jun 3, 2025 | News

As outlined in the GDUFA III Commitment Letter, these performance metrics must be reported each fiscal year.Original and PAS Review Review Time GoalActions CompletedPercent on TimePotential Range *On-Time Imminent ActionImminent Action Potential Range *Original ANDA...

Infusion Pump Intermittent Connection Issue from Smiths Medical

by Pill Pals Customer Service | Jun 3, 2025 | News

This recall involves correcting certain devices and does not involve removing them from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it without...

BsUFA III Regulatory Science Pilot Program: Progress Update

by Pill Pals Customer Service | Jun 3, 2025 | News

On This Page Date: January 22, 2025 Time: 1:00 p.m. – 3:00 p.m. ET Topic & PresentationsSpeakersBsUFA III Regulatory Science Pilot Program: Progress Update BsUFA Program Introduction & Recap from Last EngagementDarlese Solorzano, MS, MBASenior Program...

Infusion Pump Thermal Damage Issue from Smiths Medical

by Pill Pals Customer Service | Jun 3, 2025 | News

This recall involves correcting certain devices and does not involve removing them from where they are used or sold. The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it without...

FDA approves darolutamide

by Pill Pals Customer Service | Jun 3, 2025 | News

On June 3, 2025, the Food and Drug Administration (FDA) approved darolutamide (Nubeqa, Bayer Healthcare Pharmaceuticals Inc.) for metastatic castration-sensitive prostate cancer (mCSPC). The FDA previously approved darolutamide in combination with docetaxel for...